Endocyte, Inc. (NASDAQ: ECYT) today provided an update on its corporate strategy and announced financial results for the fourth quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Endocyte (ECYT) Prices 17.86M Share Common Offering at $4.20/ShFebruary 28, 2018 9:20 AM Endocyte (ECYT) Announces Proposed Common Share OfferingFebruary 28, 2018 5:45 AM Cowen Sees Favorable Risk/Reward in Endocyte (ECYT) Amid Phase III Trial of PSMA-617February 27, 2018 3:33 PM Endocyte (ECYT) Reports Supply Agreement with ITM for EndolucinBeta in Phase 3 VISION TrialFebruary 26, 2018 11:47 AM Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial ResultsFebruary 26, 2018 8:00 AM